August 2011 Vol. 6 No. 8

A power multiplier

Passion for what we do can be a powerful intrinsic motivator.

AHRQ releases Spanish medication tracking tool

The Agency for Healthcare Research and Quality has released a newly revised Spanish language medication tracking tool, “Su medicamento: Infórmese. Evite riesgos.” (“Your Medicine: Be Smart. Be Safe.”).…

FDA approves new melanoma drug

The U.S. Food and Drug Administration (FDA) has approved Zelboraf (vemurafenib) for use in patients with metastatic or unresectable melanoma who have the BRAF V600E mutation. Read more.

FDA approves treatment for hereditary angioedema

The U.S. Food and Drug Administration (FDA) has approved Firazyr (icatibant) Injection for the treatment of acute attacks of hereditary angioedema in people ages 18 years and older.…

FDA approves treatment of non-small cell lung cancer

The U.S. Food and Drug Administration (FDA) has approved Xalkori (crizotinib) to treat patients with late-stage non-small cell lung cancers who express the abnormal anaplastic lymphoma kinase (ALK)…

FDA publishes REMS list

Access a list of Risk Evaluation and Mitigation Strategies (REMS) required by the U.S. Food and Drug Administration (FDA). Read more..

Reader Survey

Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Test Your Knowledge

Which of the following statements about traumatic hyphema is true?